Back to the main directory
EarningsReview / Equity
- Hexagon - Flexing its muscles by Danske Bank Equity Research
- Nordea - Real delivery driving targets higher by Danske Bank Equity Research
- Loomis - A high quality earnings beat by Danske Bank Equity Research
- Husqvarna - Double-digit growth in 2022 by Danske Bank Equity Research
- Arjo - A bump in the road – medium-term trajectory by Danske Bank Equity Research
- Detection Technology - Buy/EUR 32 (31.50): Security market to recover in 2022-23 by Nordea
- Kone - Sell/EUR 51 (52): 2022 risks materialising, but uncertainty still high by Nordea
- Novo Nordisk - Buy/DKK 767: Strong 2022 guidance, uplifting Wegovy progress by Nordea
- Swedbank - Hold: Q4 report on the weak side but no disaster by Nordea
- Novo Nordisk (Buy, TP: DKK740.00) - Strong 2022 guidance by DnB Markets
- Euronav (Hold, TP: USD9.30) - Sector still struggling by DnB Markets
- Ossur (Buy, TP: DKK51.00) - Strong underlying outlook by DnB Markets
- Safe Bulkers (Buy, TP: USD6.20) - Rebound candidate by DnB Markets
- AAK (Buy, TP: SEK235.00) - Set for strong recovery by DnB Markets
- Alfa Laval (Hold, TP: SEK335.00) - 2022e sales intact by DnB Markets
- Kalera AS (Hold, TP: NOK9.00) - Resetting expectations and announcing proposed merger by DnB Markets
- Veoneer (Hold, TP: SEK340.00) - Trading 5% below Qualcomm bid by DnB Markets
- Avance Gas Minor model adjustments by DnB Markets
- Itaú BBA on Santander Chile: A Historical Year, ROAE at 22.8% by Itau
- Itaú BBA on Santander México: Neutral 4Q21 Results – Solid Loan Growth by Itau
- Who''s afraid of cost inflation? by BNP Paribas Exane
- The potential, the trigger, the upside by BNP Paribas Exane
- Believe by BNP Paribas Exane
- Game-changer by BNP Paribas Exane
- Growth beyond the rebound taking shape by BNP Paribas Exane
- Novo Nordisk - Ozempic drives higher growth than expected by Danske Bank Equity Research
- Axfood - Earnings growth well protected in 2022 by Danske Bank Equity Research
- Hansa Biopharma - Market access and commercial efforts progressing by Danske Bank Equity Research
- ABB - Margin pressure in H1 2022 by Danske Bank Equity Research
- Hexagon - Buy/SEK 165 (160): Excellent performance despite supply issues by Nordea
- Indutrade - Hold: Forward-leaning comments but seeing is believing by Nordea
- Lifco - Hold: Stronger organically but margin pressure persists by Nordea
- Sparebanken Vest - Hold: Stellar performance but more deposits needed by Nordea
- Telenor - Hold: Not much to write home about before 2023 by Nordea
- Norske Skog (Buy, TP: NOK55.00) - Margin expansion by DnB Markets
- Novozymes (Sell, TP: DKK410.00) - Looking for pricing power by DnB Markets
- Elekta (Buy, TP: SEK140.00) - Q3 2021/22 preview by DnB Markets
- Swedbank (Hold, TP: SEK195.00) - ROE target looking challenging by DnB Markets
- Sparebanken Vest (Hold, TP: NOK115.00) - Continues to outperform by DnB Markets
- Ncc (Buy, TP: SEK190.00) - Q4 report supports the 23e target by DnB Markets
- Hexagon AB (Buy, TP: SEK150.00) - Measuring up by DnB Markets
- Jm Ab (Sell, TP: SEK320.00) - Past still posing consensus risk by DnB Markets
- Ergomed - Healthy CRO segment rebound confirmed by Edison Investment Research
- Itaú BBA on Megacable: Strong 4Q21, as Expected; Fine-Tuning Estimates by Itau
- To infinity and beyond by BNP Paribas Exane
- Energy crunch hits UK bills by BNP Paribas Exane
- The basics of stock picking by BNP Paribas Exane
- Valuation Station - False friend by BNP Paribas Exane
- Still no fireworks by BNP Paribas Exane
- Massive backlog, little EPS changes by BNP Paribas Exane